Alaunos Therapeutics
TCRT
132 hedge funds and large institutions have $170M invested in Alaunos Therapeutics in 2018 Q2 according to their latest regulatory filings, with 14 funds opening new positions, 37 increasing their positions, 36 reducing their positions, and 15 closing their positions.
3% more repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 36
0.01% less ownership
Funds ownership: 0.27% → 0.26% (-0.01%)
1% less funds holding
Funds holding: 133 → 132 (-1)
7% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 15
25% less capital invested
Capital invested by funds: $228M → $170M (-$57.5M)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
63% less call options, than puts
Call options by funds: $1.39M | Put options by funds: $3.75M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$3.03M |
| 2 |
VIA
Vident Investment Advisory
Alpharetta,
Georgia
|
+$791K |
| 3 |
Group One Trading
Chicago,
Illinois
|
+$735K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$698K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$673K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$7.05M |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$1.6M |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$1.4M |
| 4 |
Norges Bank
Oslo,
Norway
|
-$1.14M |
| 5 |
Renaissance Technologies
New York
|
-$942K |
TCRT Hedge Fund Activity: Q2 2018 in Review
132 of the 4,385 institutional investors tracked by Wall St. Rank reported a position in Alaunos Therapeutics (TCRT) for Q2 2018, worth a combined $170M — down 25% from $228M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of TCRT and 14 opened new positions — a net loss of 1 holder — while 36 trimmed existing stakes and 37 added.
The largest buyer was BlackRock, adding an estimated $3.03M. The largest seller was State Street, cutting an estimated $7.05M.
- 132 institutional investors held Alaunos Therapeutics (TCRT) as of Q2 2018, down from 133 in Q1 2018.
- Funds reported $170M of Alaunos Therapeutics stock for Q2 2018, down 25% quarter-over-quarter.
- 14 funds opened new Alaunos Therapeutics positions in Q2 2018 and 15 closed out, a net change of -1 holder.
- The largest Alaunos Therapeutics buyer in Q2 2018 was BlackRock, an estimated $3.03M added.
- The largest Alaunos Therapeutics seller in Q2 2018 was State Street, an estimated $7.05M sold.
Based on aggregated 13F filings for Q2 2018.